AcelRx Pharmaceuticals Inc. (ACRX) Sees Large Volume Increase
Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) saw an uptick in trading volume on Monday . 983,556 shares traded hands during mid-day trading, an increase of 181% from the previous session’s volume of 350,082 shares.The stock last traded at $3.78 and had previously closed at $3.73.
A number of brokerages have commented on ACRX. Stifel Nicolaus downgraded AcelRx Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. HC Wainwright reiterated a “buy” rating on shares of AcelRx Pharmaceuticals in a research report on Monday, August 1st. Seaport Global Securities upgraded AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a research report on Friday, May 6th. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a research report on Friday, July 29th. Finally, RBC Capital Markets reiterated a “positive” rating and issued a $6.00 price objective on shares of AcelRx Pharmaceuticals in a research report on Tuesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $7.30.
The company has a 50-day moving average of $3.17 and a 200-day moving average of $3.34. The company’s market capitalization is $157.69 million.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last announced its quarterly earnings data on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The company earned $4.53 million during the quarter, compared to analysts’ expectations of $2.17 million. Analysts forecast that AcelRx Pharmaceuticals Inc. will post ($0.91) earnings per share for the current fiscal year.
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.